肺部病灶立体定向放疗联合淋巴结区域常规放疗治疗原发性肺部恶性肿瘤的可行性
本研究纳入21例原发肺部小肿瘤且远离区域淋巴结区的患者,肺部病灶行4次40-60 Gy的立体定向体部放疗(SBRT),淋巴结区行常规放疗(CRT,非小细胞肺癌66 Gy/30次,小细胞肺癌52.5 Gy/25次)。中位随访12个月,中位生存13个月,1年总生存率60.5%、局部无复发生存率84.8%、无远处转移生存率62.1%,主要失败模式为远处失败(粗发生率43%)。作者认为该联合方案似乎有效且安全,但高龄和/或合并基础肺病患者需更严格的肺剂量约束。
要点
- 21例原发肺部小肿瘤且远离淋巴结区患者接受肺部SBRT 40-60 Gy/4次联合淋巴结区CRT。
- 1年总生存率60.5%、局部无复发生存率84.8%、无远处转移生存率62.1%,主要失败模式为远处失败(粗发生率43%)。
- 3例年龄≥79岁患者发生≥3级急性放射性肺炎,其中1例合并特发性间质性肺炎。
核心结论
- 肺部病灶SBRT联合淋巴结区CRT对肺部恶性肿瘤似乎有效且安全。
- 年龄较大和/或合并基础肺病的患者需要更严格的肺剂量约束。
研究设计与样本
- 本研究纳入21例原发肺部小肿瘤且远离区域淋巴结区的患者。
- 肺部病灶行SBRT,剂量为4次40-60 Gy。
- 淋巴结区行CRT,非小细胞肺癌为30次66 Gy,小细胞肺癌为25次52.5 Gy。
主要发现
- 中位随访时间为12个月,中位生存为13个月。
- 1年总生存率为60.5%,局部无复发生存率为84.8%,无远处转移生存率为62.1%。
- 2例患者出现野内局部复发,合并野外区域复发和/或远处失败。
- 主要复发模式为远处失败,粗发生率为43%。
- 3例年龄≥79岁患者发生≥3级急性放射性肺炎,其中1例合并特发性间质性肺炎。
临床怎么用
- 作者认为肺部病灶SBRT联合淋巴结区CRT对肺部恶性肿瘤似乎有效且安全。
- 作者认为年龄较大和/或合并基础肺病的患者需要更严格的肺剂量约束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combined stereotactic body radiotherapy (SBRT) for lung lesions and conventional radiotherapy (CRT) for nodal areas may be more effective than CRT alone in patients with locally advanced lung cancer. METHODS: This study included 21 patients with small primary lung tumors distant from the regional nodal areas. The SBRT dose was 40-60 Gy in 4 fractions. CRT doses were 66 Gy in 30 fractions for non-small cell lung cancer and 52.5 Gy in 25 fractions for small cell lung cancer. RESULTS: The median follow-up duration was 12 months, and the median survival was 13 months. The 1 year overall survival, local recurrence-free survival, and distant metastasis-free survival rates were 60.5, 84.8, and 62.1%, respectively. Two patients experienced in-field local recurrence combined with out-field regional recurrence and/or distant failure. The major recurrence pattern was distant failure (crude incidence, 43%). Three patients aged ≥79 years experienced grade ≥ 3 acute radiation pneumonitis, and one also had idiopathic interstitial pneumonia. CONCLUSION: The combination of SBRT for the lung lesion and CRT for the nodal region seems to be effective and safe for lung malignancies. However, patients older in age and/or with underlying pulmonary disease require stricter lung dose constraints.
引用
- Kim YJ, Kim SS, Song SY, et al. Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies. Radiat Oncol. 2018. PMID: 29996863. doi:10.1186/s13014-018-1071-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。